



## **Starpharma presents on VivaGel<sup>®</sup> at 14<sup>th</sup> Annual Meeting of the International Herpes Management Forum<sup>®</sup>**

**Melbourne, 11 October, 2007:** Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) will today present an invited lecture at the 14<sup>th</sup> Annual Meeting of the International Herpes Management Forum (IHMF<sup>®</sup>) in Dubrovnik, Croatia.

Starpharma's presentation will focus on the development of SPL7013 Gel (VivaGel<sup>®</sup>) for the prevention of genital herpes and HIV. In addition, the presentation will highlight the fact that HSV-2, the virus that causes genital herpes, is highly prevalent globally, with 50-70% of HIV negative women in sub-Saharan Africa, and 22% of sexually active adults in the US infected.

It is estimated that by 2025, 40-50% of women in the U.S. will be infected with HSV-2. Genital herpes is a recurrent, lifelong viral infection, and is the most common cause of genital ulcer disease. Importantly, HSV-2 infection has been shown to increase the risk of both HIV acquisition and transmission through sexual intercourse. It has been estimated that 30-50% of all new HIV infections in Africa are directly due to HSV-2.

A key aim of the meeting is to develop international recommendations and guidelines on the management of herpes virus infections, and topical microbicides such as Starpharma's VivaGel<sup>®</sup>, will play a key role in prevention of genital herpes. The epidemiological data highlights the fact that VivaGel<sup>®</sup>, if shown to be effective in reducing the risk of HSV-2 infection, could potentially have a significant impact on the incidence of HIV infection.

"We are very pleased to have the opportunity to profile VivaGel<sup>®</sup> at an international scientific meeting of this calibre," Starpharma CEO Dr Jackie Fairley said.

VivaGel<sup>®</sup> is being developed as a topical vaginal microbicide for the prevention of HIV and genital herpes, and is currently under investigation in healthy female volunteers in two separate expanded safety clinical trials at sites in the U.S. and Kenya. VivaGel<sup>®</sup> also shows promise as a contraceptive agent.

---

### **About Starpharma:**

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel<sup>®</sup> (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

In the pharmaceutical field Starpharma has additional specific programs in the areas of Drug Delivery and ADME Engineering<sup>™</sup> (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells).

More broadly the company is exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.

SPL has a comprehensive IP portfolio that comprises more than 180 patents/applications issued and pending across 32 patent families - a unique level of IP concentration among nanotechnology companies.

**Dendrimers:** A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

**Microbicides:** A microbicide inactivates, kills or destroys microbes such as viruses and bacteria. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STIs. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function.

**American Depositary Receipts (ADRs):** Starpharma's ADRs trade under the code **SPHRY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York Mellon is the depositary bank. Starpharma's ADRs are listed on International OTCQX ([www.otcqx.com](http://www.otcqx.com)), a premium market tier in the U.S. for international exchange-listed companies, operated by Pink Sheets, LLC.

### **Forward Looking Statements**

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

### **For further information:**

<b>Media</b>	<b>Starpharma</b> <a href="http://www.starpharma.com">www.starpharma.com</a>	
<b>Rebecca Wilson</b> <b>Buchan Consulting</b> Tel: +61 2 9237 2800 Mob: +61 417 382 391 <a href="mailto:rwilson@bcg.com.au">rwilson@bcg.com.au</a>	<b>Dr Jackie Fairley</b>  Chief Executive Officer +61 3 8532 2704	<b>Ben Rogers</b>  Company Secretary +61 3 8532 2702 <a href="mailto:ben.rogers@starpharma.com">ben.rogers@starpharma.com</a>